Trial Profile
A Phase 1-2 Study of Ti-061 Alone and in combination with other anti-cancer agents in Patients with Advanced Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2017
Price :
$35
*
At a glance
- Drugs TI 061 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Arch Oncology
- 03 Oct 2017 Status changed from recruiting to discontinued.
- 16 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology